GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma
Active, not recruiting · NCT06566547 · Registry updated 2026-05-27Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| GR1803 Injection in Patients With Relapsed/Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-05-27 | NCT06566547 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 14 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| he First Affiliated Hospital, Zhejiang University School of Medicine | Hangzhou | China | 1 |